Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
-99.12%
↑ 22% above average
Average (39q)
-126.60%
Historical baseline
Range
High:132.56%
Low:-3130.77%
CAGR
+3.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -99.12% |
| Q2 2025 | 39.74% |
| Q1 2025 | -14.00% |
| Q4 2024 | -344.47% |
| Q3 2024 | 128.67% |
| Q2 2024 | 28.03% |
| Q1 2024 | 16.97% |
| Q4 2023 | 41.68% |
| Q3 2023 | 13.89% |
| Q2 2023 | -785.22% |
| Q1 2023 | 132.56% |
| Q4 2022 | -0.91% |
| Q3 2022 | -20.03% |
| Q2 2022 | -1.05% |
| Q1 2022 | -13.44% |
| Q4 2021 | 17.63% |
| Q3 2021 | 0.54% |
| Q2 2021 | -5.18% |
| Q1 2021 | -6.61% |
| Q4 2020 | -1073.52% |
| Q3 2020 | 90.23% |
| Q2 2020 | 14.88% |
| Q1 2020 | -3130.77% |
| Q4 2019 | 105.02% |
| Q3 2019 | 12.70% |
| Q2 2019 | 23.68% |
| Q1 2019 | -111.33% |
| Q4 2018 | -27.90% |
| Q3 2018 | 15.15% |
| Q2 2018 | 8.84% |
| Q1 2018 | -52.53% |
| Q4 2017 | -5.61% |
| Q3 2017 | -2.09% |
| Q2 2017 | 23.96% |
| Q1 2017 | -70.82% |
| Q4 2016 | 48.82% |
| Q3 2016 | 28.45% |
| Q2 2016 | -60.91% |
| Q1 2016 | -6.43% |
| Q4 2015 | -23.56% |